Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ · Manufacturing · Pharmaceutical preparations
BOLT price, last 12 months
Key stats
- Previous close
- $5.10
- Open
- $5.20
- Day range
- $5.06 – $5.30
- 52-week range
- $3.10 – $7.78
- Volume
- 35.6K
- Avg volume (20 days)
- 759.4K
- Market cap
- $14.3M
Performance
Technicals and fundamentals
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $14.3M